Ventana Medical Systems, Inc.

Oregon Health & Science University

Mayo Foundation for Medical Education and Research

University of California

The United States Government As Represented by the Department of Veterans Affairs

F. Hoffmann-la Roche Ag

Spring Bioscience Corporation

The United States of America As Represented by the Deparment of Vetererans Affairs

Kandavel Shanmugam

Michael S Barnes

Joe W Gray

Srinivas Chukka

Joerg Bredno

Fernando Jose Rebelo Do Couto

Christophe Chefd'hotel

Thomas M Grogan

David Chafin

Benjamin C Stevens

Zhiming Liao

Yifei Zhu

Karl Eric Garsha

Esteban Roberts

Brian Jay Druker

Shalini Singh

Pradipta Ghosh

Thomas Jacob

Franklin Ventura

Tania Vu

Bonnie LaFleur

Junming Zhu

Wen-Wei Liu

Rebecca C Bowermaster

Andrea Muranyi

Damien Ramunno-Johnson

Tothu Tania Vu

Song Hu

Karl Garsha

Katherine Leith

Frank A Sinicrope

Ulrich-Peter Rohr

Frank Ventura

Fernando Couto

Tothu Vu

Brian Jay Drucker

The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin

Immune context scores are calculated for stage III colorectal tumor tissue samples using continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a density of human CD3+ cells in a region of interest including an invasive margin. A continuous scoring function is then applied to a feature vector, the output of which is an immune context score. The immune context score may then be plotted as a function of a diagnostic or treatment metric, such as a prognostic metric (e.g. overall survival, disease-specific survival, progression-free survival) or a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and/or treatment decisions.

Methods and systems for evaluation of immune cell infiltrate in stage III colorectal cancer

Immune context scores are calculated for tumor tissue samples using continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a quantitative measure of human CD3 or total lymphocyte counts. A continuous scoring function is then applied to a feature vector including the feature metric and at least one additional metric related to an immunological biomarker, the output of which is an immune context score. The immune context score may then be plotted as a function of a diagnostic or treatment metric, such as a prognostic metric (e.g. overall survival, disease-specific survival, progression-free survival) or a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and/or treatment decisions.

Methods and systems for evaluation of immune cell infiltrate in tumor samples

Methods, systems, and apparatuses for detecting and describing heterogeneity in a cell sample are disclosed herein. A plurality of fields of view (FOV) are generated for one or more areas of interest (AOI) within an image of the cell sample are generated. Hyperspectral or multispectral data from each FOV is organized into an image stack containing one or more z-layers, with each z-layer containing intensity data for a single marker at each pixel in the FOV. A cluster analysis is applied to the image stacks, wherein the clustering algorithm groups pixels having a similar ratio of detectable marker intensity across layers of the z-axis, thereby generating a plurality of clusters having similar expression patterns.

Methods, systems, and apparatuses for quantitative analysis of heterogeneous biomarker distribution

Growing community of inventors

Chandler, AZ, United States of America

Kandavel Shanmugam